哈三联(002900) - 2025 Q1 - 季度财报

Revenue and Profit - The company's revenue for Q1 2025 was ¥205,027,782.58, a decrease of 16.93% compared to ¥246,819,438.23 in the same period last year[5] - The net profit attributable to shareholders was a loss of ¥28,845,105.91, representing a decline of 253.52% from a profit of ¥18,789,452.77 in the previous year[5] - Total revenue decreased to ¥205,027,782.58 from ¥246,819,438.23, a decline of approximately 17%[18] - Net profit turned negative at -¥29,795,441.26 compared to a profit of ¥17,414,092.70 in the previous period, indicating a significant decline[18] - Operating profit also fell to -¥35,207,091.55 from ¥18,914,975.05, marking a substantial decrease[18] - The total comprehensive income amounted to -29,795,441.26, down from 17,414,092.70 in the previous period[19] Earnings Per Share - Basic and diluted earnings per share were both -¥0.09, down 250.00% from ¥0.06 in the previous year[5] - The basic and diluted earnings per share were both -0.09, compared to 0.06 in the previous period[19] Cash Flow - The net cash flow from operating activities improved significantly to ¥86,305,192.39, a 341.32% increase from a negative cash flow of ¥35,763,547.76 in the same period last year[5] - Cash inflows from operating activities totaled 309,894,685.22, while cash outflows were 223,589,492.83[21] - The net cash flow from investing activities was -59,333,626.64, compared to -95,557,908.40 in the previous period[21] - Cash inflows from financing activities were 548,188,657.04, with cash outflows of 458,481,029.99, resulting in a net cash flow of 89,707,627.05[21] - The ending cash and cash equivalents balance was 672,160,767.37, up from 615,495,077.20 in the previous period[22] Assets and Liabilities - Total assets at the end of the reporting period were ¥3,727,905,773.09, a decrease of 1.91% from ¥3,800,468,270.17 at the end of the previous year[5] - Total liabilities decreased to ¥1,592,613,755.20 from ¥1,636,313,285.80, a reduction of approximately 3%[15] - Owner's equity decreased to ¥2,135,292,017.89 from ¥2,164,154,984.37, a decline of about 1.3%[15] Expenses - Sales expenses decreased by 34.67% to ¥52,760,862.47 compared to ¥80,759,821.86 in the same period last year, mainly due to the impact of drug procurement policies[8] - Financial expenses increased by 165.74% to ¥4,377,685.71 from -¥6,659,002.31 in the previous year, primarily due to a significant reduction in interest income[8] - Research and development expenses decreased to ¥18,780,039.34 from ¥24,691,842.55, a reduction of approximately 24%[18] Government Subsidies and Other Income - The company received government subsidies amounting to ¥3,996,544.70, which were included in the current period's profit and loss[6] - Received cash from other operating activities increased to ¥63,055,036.01, a 233.16% increase compared to the previous period, mainly due to significant government subsidies and interest income from long-term loans[10] - Cash received from investment recoveries was ¥30,000,000.00, marking a 100% increase due to the redemption of financial products[10] - Cash received from investment income was ¥9,059,178.08, a 100% increase, resulting from cash dividends received from an associate company[10] Shareholder Information - The total number of common shareholders at the end of the reporting period was 29,272, with the largest shareholder holding 39.10% of the shares[11] - The largest shareholder, Qin Jianfei, has pledged 36,000,000 shares, representing a significant portion of his holdings[11]